HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $16.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also commented on ESPR. Needham & Company LLC decreased their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Esperion Therapeutics Stock Performance

ESPR opened at $2.54 on Wednesday. Esperion Therapeutics has a 52-week low of $1.16 and a 52-week high of $3.40. The firm has a market cap of $500.48 million, a P/E ratio of -3.97 and a beta of 0.96. The business’s fifty day moving average is $2.08 and its 200-day moving average is $2.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ESPR. BOKF NA acquired a new position in Esperion Therapeutics during the 2nd quarter worth approximately $26,000. Traphagen Investment Advisors LLC bought a new stake in shares of Esperion Therapeutics during the third quarter worth $27,000. Xponance Inc. acquired a new position in shares of Esperion Therapeutics during the second quarter worth $28,000. National Bank of Canada FI increased its holdings in shares of Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new position in shares of Esperion Therapeutics in the 2nd quarter valued at $44,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.